3,4-二氢-2H-1,4-噻嗪-3,5-二羧酸 | 86360-62-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3,4-二氢-2H-1,4-噻嗪-3,5-二羧酸
• 英文名称: lanthionine ketimine
• 英文别名: 3,4-dihydro-2H-[1,4]thiazine-3,5-dicarboxylic acid；3,4-Dihydro-2H-1,4-thiazine-3,5-dicarboxylic acid
• CAS: 86360-62-5
• 化学式: C₆H₇NO₄S
• mdl: MFCD08689755
• 分子量: 189.192
• InChiKey: PKFNRZOFABOFSP-UHFFFAOYSA-N

物化性质

• 熔点：
  190-195°(dec)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3,4-二氢-2H-1,4-噻嗪-3,5-二羧酸 、 硫代异氰酸苯酯 生成 1-oxo-2-phenyl-3-sulfanylidene-5,6-dihydroimidazo[5,1-c][1,4]thiazine-5-carboxylic acid
  参考文献：
  名称：

  PECCI, L.;COSTA, M.;PINNEN, F.;ANTONUCCI, A.;CAVALLINI, D., J. CHROMATOGR.-BIOMED. APPL., 426,(1988) N 1, 183-187

  摘要：

  DOI：
• 作为产物：
  描述：

  L-半胱氨酸 、 3-溴丙酮酸乙酯 以 水 为溶剂， 以32%的产率得到3,4-二氢-2H-1,4-噻嗪-3,5-二羧酸
  参考文献：
  名称：

  Pyruvate derivatives

  摘要：

  某些已知和新颖的丙酮酸衍生物在恢复或保护氧化能力细胞中的代谢完整性方面特别活跃，这些细胞曾经遭受氧气匮乏。这些由丙酮酸衍生的化合物包括但不限于肟、酰胺、丙酮酸类似物、改性丙酮酸类似物、丙酮酸酯（例如聚醇-丙酮酸酯、丙酮酸硫酯、甘油-丙酮酸酯和二羟基乙酮-丙酮酸酯）。这些丙酮酸衍生物（包括单重构体、单立体异构体和重构体和/或立体异构体混合物以及其药学上可接受的盐）可用于制造用于治疗由氧化应激引起的多种疾病的药物组合物。

  公开号：

  US20030013847A1

文献信息

• COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS
  申请人：Chodorowski-Kimmes Sandrine

  公开号：US20100239509A1

  公开（公告）日：2010-09-23

  The present patent application relates to a cosmetic or dermatological composition comprising, in a cosmetically or dermatologically acceptable medium, a polymer comprising: (a) a polymer backbone that may be obtained by reaction: of a polyol comprising 3 to 6 hydroxyl groups; of a monocarboxylic acid containing 6 to 32 carbon atoms; of a polycarboxylic acid comprising at least two carboxylic groups COOH, and/or of a cyclic anhydride such as a polycarboxylic acid and/or of a lactone comprising at least one carboxylic group COOH; and (b) at least one junction group linked to the said polymer backbone and capable of establishing H bonds with one or more partner junction groups, each pairing of a junction group involving at least three H (hydrogen) bonds. The patent application also concerns a cosmetic treatment process using the said composition.

  本专利申请涉及一种化妆品或皮肤科学组合物，包括在化妆品或皮肤科学上可接受的介质中，包含以下聚合物的组合物：(a) 由以下反应得到的聚合物骨架：含有3至6个羟基的多元醇；含有6至32个碳原子的一元羧酸；至少含有两个羧基COOH的多元羧酸，和/或类似多元羧酸的环酐和/或至少含有一个羧基COOH的内酯；以及(b) 至少一个连接到所述聚合物骨架的连接基团，并能够与一个或多个配对连接基团建立H键，每个连接基团的配对涉及至少三个H（氢）键。该专利申请还涉及使用所述组合物的化妆品处理过程。
• COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION
  申请人：GIUSTINIANI Pascal

  公开号：US20090028807A1

  公开（公告）日：2009-01-29

  The present application relates to a cosmetic or pharmaceutical, in particular lipstick, composition comprising a polycondensate The application also relates to a method of cosmetic treatment using the composition, the polycondensate thus defined and a method of preparing the polycondensate.

  本申请涉及一种化妆品或药用品，特别是口红，包括聚缩酸酯的组合物。该申请还涉及一种使用该组合物进行化妆处理的方法，所述聚缩酸酯的定义以及一种制备聚缩酸酯的方法。
• COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT
  申请人：Malle Gerard

  公开号：US20100272660A1

  公开（公告）日：2010-10-28

  The present application relates to a cosmetic or pharmaceutical composition comprising a polycondensate capable of being obtained by the reaction of the following monomers alone: of 10 to 30% by weight, relative to the total weight of the polycondensate, of one or more polyols comprising 3 to 6 hydroxyl groups; of 30 to 80% by weight, relative to the total weight of the polycondensate, of one or more linear, branched and/or cyclic, saturated or unsaturated, non-aromatic monocarboxylic acids comprising 6 to 32 carbon atoms; of 1 to 40% by weight, relative to the total weight of the polycondensate, of one or more polycarboxylic acids and/or cyclic anhydrides of such a polycarboxylic acid and/or lactones comprising at least one COOH group; and optionally of 0.1 to 15% by weight, relative to the total weight of the polycondensate, of one or more silicones having a hydroxyl and/or carboxyl functional group. The application also relates to a method of cosmetic treatment using the said composition, and the polycondensate thus defined.

  本申请涉及一种化妆品或药用组合物，包括由以下单体反应而得的聚缩酸酯：相对于聚缩酸酯的总重量，占10至30%的一种或多种含有3至6个羟基的多元醇；占30至80%的一种或多种线性、支链和/或环状、饱和或不饱和、非芳香族的单羧酸，含有6至32个碳原子；占聚缩酸酯总重量的1至40%的一种或多种多羧酸和/或多羧酸的环状酐和/或含有至少一个COOH基团的内酯；以及可选地占聚缩酸酯总重量的0.1至15%的一种或多种硅氧烷，具有羟基和/或羧基官能团。该申请还涉及使用所述组合物进行化妆处理的方法，以及如此定义的聚缩酸酯。
• Analysis of lanthionine ketimine ethyl ester in mouse serum, whole blood and tissues using ultrahigh-pressure liquid chromatography/tandem mass spectrometry
  作者：Ruth N. Muchiri、Katarzyna E. Kowal、Kenneth Hensley、Douglas L. Feinstein、Richard B. van Breemen

  DOI：10.1002/rcm.8263

  日期：2018.11.30

  An ultrahigh-pressure liquid chromatography/tandem mass spectrometry (UHPLC/MS/MS) assay was developed to evaluate bioavailability by measuring these compounds in mouse serum, whole blood and brain tissue. METHODS Following administration of LKE to mice for 3 days in chow at 300 ppm, the animals were sacrificed, and LKE was extracted from serum, whole blood and brain tissues through protein precipitation

  进行多种神经退行性疾病治疗的临床前研究已经确定了羊毛硫氨酸酮亚胺（LK）及其单乙酯衍生物（LKE）是潜在的候选药物。开发了超高压液相色谱/串联质谱（UHPLC / MS / MS）测定法，通过测量小鼠血清，全血和脑组织中的这些化合物来评估其生物利用度。方法将LKE以300 ppm的食物在小鼠体内连续3天给药后，处死动物，并用冷甲醇通过蛋白质沉淀从血清，全血和脑组织中提取LKE。为了增强色谱分离和电喷雾电离，使用重氮甲烷将LK甲基化。使用C18反相UHPLC进行分离 使用具有正离子电喷雾电离，碰撞诱导的离解和选定反应监测的在线三重四极杆质谱仪进行定量测量。甲苯磺丁酰胺用作内标。结果LKE显示良好的恢复，血清中77-90％，脑组织中82-8％。从0.005到4.6μM的八点标准曲线是线性的（R2 0.998）。在小鼠血清中检测到的平均LKE为277.42 nM，而全血中的浓度为38 nM。在脑
• SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL
  申请人：Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

  公开号：EP3006023A1

  公开（公告）日：2016-04-13

  Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.

  本文提供了治疗神经精神疾病（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症和双相情感障碍）的方法和组合物。这些方法需要给被诊断为患有神经精神障碍（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症、双相情感障碍等）或有神经精神障碍风险的患者施用苯甲酸、苯甲酸盐和/或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物，并与神经药剂（如抗精神病药、抗精神病药、抗精神病药、抗精神病药）结合使用、苯甲酸、苯甲酸盐或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物的用量足以提高神经药剂的药效。